Detection of BCR/ABL gene rearrangement and the elimination of rearranged clone in chronic myelocytic leukemia patients

American Journal of Hematology

Volumn 63, Issue 2, 2000, Pages 85-89

  Eren, E ^a,c   Aytac, U ^a   Tetik, E ^a   Akman, O ^a   Kansu, E ^b   Gunduz, U ^a  

^a MIDDLE EAST TECHNICAL UNIVERSITY   (Turkey)

^b HACETTEPE UNIVERSITY   (Turkey)

^c MARMARA UNIVERSITY   (Turkey)

Author keywords

Bcr abl; Chronic myelocytic leukemia; CML; Interferon ; Ph; RT PCR

Indexed keywords

ALPHA INTERFERON;

ADULT; ARTICLE; CHILD; CHROMOSOME BREAKAGE; CHRONIC MYELOID LEUKEMIA; CLINICAL ARTICLE; CYTOGENETICS; FEMALE; GENE REARRANGEMENT; HUMAN; MALE; PRIORITY JOURNAL; TURKEY (REPUBLIC);

ADULT; BLOTTING, SOUTHERN; BONE MARROW CELLS; CELLS, CULTURED; CHILD; CHROMOSOMES, HUMAN, PAIR 22; CLONE CELLS; DRUG ADMINISTRATION SCHEDULE; FEMALE; FOLLOW-UP STUDIES; GENE REARRANGEMENT; GENES, ABL; HUMANS; INTERFERON TYPE I, RECOMBINANT; LEUKEMIA, MYELOID, CHRONIC; MALE; META-ANALYSIS; MIDDLE AGED; PHILADELPHIA CHROMOSOME; RESTRICTION MAPPING; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION; RNA, MESSENGER; TIME; TRANSLOCATION, GENETIC;

EID: 0033978095     PISSN: 03618609     EISSN: None     Source Type: Journal    
DOI: 10.1002/(SICI)1096-8652(200002)63:2<85::AID-AJH5>3.0.CO;2-L     Document Type: Article

References (19)

1. Nowel PC, Hungerford DA. A minute chromosome in human chronic granulocytic leukemia. Science 1960; 132:1497.
2. Rowley JD. A new consistent chromosomal abnormality in CML identified by quinacrine fluorescence and Giemsa staining. Nature 1973; 243:290.
3. Sandberg A. Chromosomal and causation of human cancer leukemia XL. The Ph′ and other translocations in CML. Cancer I980;46:2221.
4. Kurzrock R, Gutterman JV, Talpaz M. The molecular genetics of Philadelphia chromosome positive leukemias. New Engl J Med 1988;319(15):990.
5. Bartram CR, De Klien A, Hagemeijer A, van Agthoven T, Geurts van Kessel A, Bootsma D, Grosveld G, Ferguson-Smith MA, Davies T, Stone M, Heisterkamp N, Stephenson JR, Groffen J. Translocation of the c-abl oncogene correlates with the presence of a Ph′ chromosome in CML. Nature 1983;306:277.
6. Bernards A, Rubin CM, Westblock CA, Paskind M, Baltimore D. The first intron in the human c-abl gene is at least 200 kb long and is the target for translocation in CML. Mol Cell Biol 1987;7:3231.
7. Kagan J. Molecular biology of chromosomal aberrations in leukemia/ lymphoma. Hematol Pathol 1993;7(3):159.
8. Konopka JB, Witte ON. Detection of c-abl tyrosine kinase activity in vitro permits direct comparison of normal and altered abl gene product. Mol Cell Biol 1985;5:3116.
9. Pandergast AM, Muller AJ, Havlik MH, Maru V, Witte ON. bcr Sequences essential for transformation by the bcr-abl oncogene bind to the abl SH2 regulatory domain in a non-phosphotyrosine dependent manner. Cell 1991;66(1):161.
10. Talpaz M, Kantarjian HM, McCredie KB, Kaeting MJ, Trujillo J, Gutterman JU. Interferon-a produces sustained cytogenetic response in CML. Ann Intern Med 1991;114:532.
11. Harder DG, Klinger HP. An international system for human cytogenetic nomenclature. Cytogenet Cell Genet I978;21:309.
12. Hermans A, Gow J, Selleri L, Von Lindern M, Hagemeijer A, Wiedeman LM, Grosveld G. bcr-abl Oncogene activation in Ph′ chromosome positive ALL. Leukemia 1988;2(10):628.
13. Chomczynski P, Sacci N. Single step method of RNA isolation by acid guanidinium thiocyanide phenol-chloroform extraction. Anal Biochem 1987;162:156.
14. Lion T, Gaiger A, Henn T, Geissler K, Lechner K, Haas OA. Red cell aplasia in a case of Ph′ negative, bcr/abl positive CML with a t(12: 14)(q23:q11). Cancer Genet Cytogenet 1991;56:189.
15. Lion T, Izraeli S, Traudi H, Gaiger A, Mor W, Gadner H. Monitoring of residual disease in CML by quantitative PCR. Leukemia 1992;6(6): 495.
16. Bilhou-Mabera I, Viard F, Marit G, Gharbi MJ, Salzes S, Reiffers J, Broustet A, Bernard P. Complete cytogenetic conversion in CML patients undergoing a-interferon therapy; follow-up with RT-PCR. Leukemia 1992;6(6):595.
17. Opalka B, Wandl UB, Becher R, Kloke O, Nagel-Hiemke M, Moritz T, Beer U, Seeber S, Niederle N. Minimal residual disease in patients with CML undergoing long-term treatment with recombinant interferon-α 2b alone or combination with interferon-γ. Blood 1991;9: 2188.
18. Martiat P, Maisin D, Philippe M, Ferrant A, Michaux JL, Casimann JJ, Van Der Berghe H. Detection of residual bcr/abl transcripts in CML patients in complete remission using the PCR and nested primers. Br J Haemetol 1990;7:335.
19. Ishiyama K. Molecular elimination of Ph 1 clone in CML patient with interferon-α alone. Leukemia 1994;8:2243.